Agios [AGIO] vs Bio-Techne [TECH] Detailed Stock Comparison

Agios

NASDAQ
Loading...

Bio-Techne

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Agios wins in 10 metrics, Bio-Techne wins in 8 metrics, with 0 ties. Agios appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricAgiosBio-TechneBetter
P/E Ratio (TTM)3.59136.85Agios
Price-to-Book Ratio1.725.08Agios
Debt-to-Equity Ratio3.5623.14Agios
PEG Ratio0.25-0.96Bio-Techne
EV/EBITDA-3.2130.42Agios
Profit Margin (TTM)1,590.42%6.02%Agios
Operating Margin (TTM)-1,020.12%36.30%Bio-Techne
EBITDA Margin (TTM)N/A36.30%N/A
Return on Equity64.05%3.68%Agios
Return on Assets (TTM)-25.71%6.30%Bio-Techne
Free Cash Flow (TTM)$-391.53M$256.55MBio-Techne
Dividend YieldN/A0.79%N/A
1-Year Return-4.13%-15.59%Agios
Price-to-Sales Ratio (TTM)57.578.04Bio-Techne
Enterprise Value$1.46B$10.07BBio-Techne
EV/Revenue Ratio35.798.26Bio-Techne
Gross Profit Margin (TTM)86.33%62.72%Agios
Revenue per Share (TTM)$1$8Bio-Techne
Earnings per Share (Diluted)$11.29$0.46Agios
Beta (Stock Volatility)0.831.48Agios
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Agios vs Bio-Techne Stock Performance Analysis

Loading Price Chart...

Agios
Bio-Techne
Agios Stock Overview | Bio-Techne Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Agios0.96%4.13%12.30%16.13%57.88%28.42%
Bio-Techne-1.64%18.55%14.43%20.14%18.37%-13.37%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Agios-4.13%51.61%13.99%-42.36%43.32%43.32%
Bio-Techne-15.59%-12.43%-6.78%160.83%298.20%351.64%

News Based Sentiment: Agios vs Bio-Techne

Agios

News based Sentiment: MIXED

October brought a blend of positive and negative developments for Agios Pharmaceuticals. While the revenue beat and stock surge are encouraging, the EPS miss, PDUFA extension, and insider selling introduce uncertainty. The upcoming PDUFA decision and Q3 earnings report will be crucial catalysts for the stock's performance.

View Agios News Sentiment Analysis

Bio-Techne

News based Sentiment: MIXED

Bio-Techne experienced a strong month with significant stock gains fueled by positive earnings and a broader healthcare sector rally. However, analyst concerns regarding organic growth and declining free cash flow create a mixed investment picture, requiring investors to carefully weigh the potential risks and rewards.

View Bio-Techne News Sentiment Analysis

Performance & Financial Health Analysis: Agios vs Bio-Techne

MetricAGIOTECH
Market Information
Market Cap i$2.35B$9.80B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i539,2503,192,556
90 Day Avg. Volume i742,3232,630,039
Last Close$40.89$61.92
52 Week Range$23.42 - $62.58$46.01 - $80.80
% from 52W High-34.66%-23.37%
All-Time High$138.85 (Jan 12, 2015)$135.96 (Sep 20, 2021)
% from All-Time High-70.55%-54.46%
Growth Metrics
Quarterly Revenue Growth0.45%0.04%
Quarterly Earnings Growth0.45%0.04%
Financial Health
Profit Margin (TTM) i15.90%0.06%
Operating Margin (TTM) i-10.20%0.36%
Return on Equity (TTM) i0.64%0.04%
Debt to Equity (MRQ) i3.5623.14
Cash & Liquidity
Book Value per Share (MRQ)$23.60$12.38
Cash per Share (MRQ)$16.16$1.04
Operating Cash Flow (TTM) i$-405,998,016$287.56M
Levered Free Cash Flow (TTM) i$-250,385,120$313.92M
Dividends
Last 12-Month Dividend Yield iN/A0.79%
Last 12-Month Dividend iN/A$0.40

Valuation & Enterprise Metrics Analysis: Agios vs Bio-Techne

MetricAGIOTECH
Price Ratios
P/E Ratio (TTM) i3.59136.85
Forward P/E i-6.6628.74
PEG Ratio i0.25-0.96
Price to Sales (TTM) i57.578.04
Price to Book (MRQ) i1.725.08
Market Capitalization
Market Capitalization i$2.35B$9.80B
Enterprise Value i$1.46B$10.07B
Enterprise Value Metrics
Enterprise to Revenue i35.798.26
Enterprise to EBITDA i-3.2130.42
Risk & Other Metrics
Beta i0.831.48
Book Value per Share (MRQ) i$23.60$12.38

Financial Statements Comparison: Agios vs Bio-Techne

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)AGIOTECH
Revenue/Sales i$8.73M$316.96M
Cost of Goods Sold i$1.09M$118.15M
Gross Profit i$7.64M$198.81M
Research & Development i$72.74M$26.03M
Operating Income (EBIT) i$-106.63M$116.69M
EBITDA i$-105.35M$6.43M
Pre-Tax Income i$-89.29M$-22.86M
Income Tax iN/A$-5.18M
Net Income (Profit) i$-89.29M$-17.68M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)AGIOTECH
Cash & Equivalents i$78.96M$162.19M
Total Current Assets i$968.62M$608.30M
Total Current Liabilities i$52.37M$175.85M
Long-Term Debt i$35.74M$429.96M
Total Shareholders Equity i$1.47B$1.92B
Retained Earnings i$-238.21M$1.07B
Property, Plant & Equipment i$11.07M$73.40M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)AGIOTECH
Operating Cash Flow i$-86.93M$7.55M
Capital Expenditures i$-875,000$-4.89M
Free Cash Flow i$-88.00M$93.31M
Debt Repayment iN/A$-50.00M
Common Stock Repurchase iN/A$-100.06M

Short Interest & Institutional Ownership Analysis

MetricAGIOTECH
Shares Short i4.74M5.27M
Short Ratio i6.152.59
Short % of Float i0.08%0.04%
Average Daily Volume (10 Day) i539,2503,192,556
Average Daily Volume (90 Day) i742,3232,630,039
Shares Outstanding i57.16M154.97M
Float Shares i51.35M153.71M
% Held by Insiders i0.02%0.00%
% Held by Institutions i1.12%1.04%

Dividend Analysis & Yield Comparison: Agios vs Bio-Techne

MetricAGIOTECH
Last 12-Month Dividend iN/A$0.40
Last 12-Month Dividend Yield iN/A0.79%
3-Year Avg Annual Dividend iN/A$0.35
3-Year Avg Dividend Yield iN/A0.12%
3-Year Total Dividends iN/A$1.04
Ex-Dividend DateN/AAug 18, 2025